Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) has received US Food and Drug Administration’s (USFDA) approval for acquired immune deficiency syndrome (AIDS) treatment drug nevirapine. The drug is a generic version of German drug-maker Boehringer Ingelheim's Viramune tablets.
Recently, the company had announced that it is planning to launch the Fixed-Dose combination of ‘Artesunate (AS) 1 + Mefloquine (MQ) 2’ for the treatment of uncomplicated P. falciparum malaria. The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P. falciparum malaria and is recommended by the World Health Organization (WHO).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1666.00 |
| Dr. Reddys Lab | 1229.50 |
| Cipla | 1228.15 |
| Zydus Lifesciences | 934.00 |
| Lupin | 2329.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: